Ripple Therapeutics Analysis: $79M Raised
What is Ripple Therapeutics?
Ophthalmic therapeutics with polymer-free drug delivery
Location
Toronto, Canada
Employees
11-50
Founded
2019
Product Features & Capabilities
- IBE-814 IVT intravitreal dexamethasone prodrug implant
- RTC-620 biodegradable intracameral implant for glaucoma
- Prodrug technology for sustained drug delivery
Use Cases
Treat diabetic macular edema with IBE-814 IVT implant; Manage retinal vein occlusion using sustained release implants; Develop glaucoma therapies with RTC-620 implant; Conduct preclinical studies for dry AMD/GA; Collaborate with AbbVie for glaucoma management solutions
Other Considerations
Raised $10M in seed capital; Secured $15M Series A financing; Partnered with AbbVie for glaucoma therapy development; Collaborated with Glaukos for sustained release implants
